NEWS & EVENTS

Latest news and upcoming events

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial
25 May 2023

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

Upcoming events

  • Biospain
    26 - 28 September 2023,
    Barcelona

    download

  • Bio€quity Europe
    14 - 16 May 2023,
    Dublin

    download

  • Swiss Biotech Day
    24 - 25 April 2023,
    Switzerland

    download
Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy<
31 May 2023

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market
Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference<
31 May 2023

Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference

Adam Levy will be giving a presentation at the Jefferies Healthcare Conference at 9:30 a.m. ET June 9th 2023
Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline<
30 May 2023

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

Strengthening of strategic option license agreement to cover additional novel ADC targets
VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial<
25 May 2023

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

Funding to obtain IND approval for its lead compound VMX-C001 and to complete preparations for the pivotal clinical trial
ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors<
23 May 2023

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis<
23 May 2023

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

The study is designed to investigate the safety and efficacy of GB0139 in patients with IPF
SparingVision Presents New Data on SPVN20 Program at ASGCT 2023<
22 May 2023

SparingVision Presents New Data on SPVN20 Program at ASGCT 2023

First oral presentation on SPVN20 in a major scientific and medical conference

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update<
16 May 2023

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference<
15 May 2023

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

Elisabet de los Pinos, will participate in a fireside chat at the JMP Securities Life Sciences Conference
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights<
12 May 2023

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

U.S. Food and Drug Administration (FDA) Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal Melanoma

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.